Medicinal plants have been of great importance to human health care since the advent of medicine. A huge array of molecules has been obtained from these phytopharmaceutical-yielding species that have influenced human lives since the beginning of plant-based life-saving medicines. Some of these molecules have taken the form of taxol, aspirin, and artemisinin. With the flourishing era of highthroughput next generation sequencing technologies, a hot pursuit for sequencing the genomes and transcriptomes of these life-saving plants is underway. Although few genomes have been sequenced or are currently being addressed, the number of transcriptomes sequenced has sky-rocketed in the last couple of years and continues to surge forward with immense pace, covering all important genera of medicinal plants. I have attempted to provide the current status, progress, opportunities, and challenges of these sequencing endeavors in this comprehensive and updated review. It is my hope that this information will provide both specialists and non-specialists with the current trends and future directions of this interesting category of plants.
Introduction
Metabolites are small chemical entities present in living organisms with a molecular weight of less than 1000 Da. The collection of such small molecules in organelles, cells, tissues, organs and bio-fluids at a particular time are known as the metabolome. The plant metabolome is estimated to be at a size of 200,000 Da or more (Goodacre et al. 2004) . Furthermore, a statistical analysis predicted the number of plant metabolites to fall in a range between 200,000 and 1,000,000 compounds (Afendi et al. 2012) . Historically, the metabolomes of these plants that yield medicinal compounds, known as phytomedicinals, are a result of the 'secondary' and 'specialized' metabolism operative contained within them.
The World Health Organization (WHO) recorded that 80% of the world's developing population depends primarily on herbal medicine for basic healthcare (Vines, 2004) . These phytomedicineyielding plant species that are used in herbal medicine are generally known as medicinal plants. They belong to typical taxonomic families, mostly dicot angiosperms (i.e., Lamiaceae, Asteraceae, Apocyanaceae, Scrophulariaceae, and Solanaceae). Plant-based drugs have traditionally been extracted and isolated in small or industrial scale quantities using the original plant materials. However, this method of harvesting these drugs is drastically changing, with the recombinant production of phytomedicinals using microbial models emerging. Yeast, Escherichia coli, and a host of other models are the microbes being used to extract taxol, artemisinin and other drugs (Xiao et al., 2013) . In order to obtain a detailed understanding of the specialized metabolism operative in these plants, metabolite profiling, biochemical approaches, natural products chemistry, gene-cloning, protein purification, and gene expression approaches were used. These techniques yielded information on specific proteins, novel transcripts, and chemical processes being undergone in these plants. The technological breakthroughs achieved in the past couple of decades have enabled high throughput studies of plants' genomes, transcriptomes, proteomes, and metabolomes with a fair amount of time, effort, and costs. Out of ~ 370,000 known plant species only ~80,000 species are represented by at least a single GenBank entry (Carlos et al., 2012) .
Plant sequencing efforts have been centered mostly on angiosperms; more specifically, the eudicots that include economically important crops. For example, expressed sequence tag (EST) sequencing and mRNA profiling using either microarrays or serial analysis of gene expression (SAGE), and digital gene expression (DGE) now allow for a comprehensive analysis of the transcriptome (Sumner et al., 2003) . Additionally, the advent of high throughput methods, like next generation sequencing platforms, has enabled whole-genome sequencing (WGS) advances. Unfortunately, hardly any compilations have been attempted to gauge the current progress of medicinal plant genomes; although transcriptomes have been discussed recently (Xiao et al., 2013) . In fact, the compilation of Chen et al. 2011 provides a comprehensive overview of the development of sequencing technologies, summarizes the sequenced plant genomes, discusses the approaches in sample preparation for sequencing, genome assembly, annotation, and gene family mining, but largely fails to identify the advances in medicinal plant genomics in a realistic sense. On the other hand, most genome sequencing attempts have focused on model plants i.e., dicot model Arabidopsis thaliana, monocot model rice (Oryza sativa), unicellular viridiplantae Chlamydomonas, woody plant model Populus trichocarpa and mostly other commercially beneficial plants such as coffee, soybean, castor bean, strawberry, maize, sorghum, papaya, grape, cotton, ginseng, apple, rubber, cucumber and others. Thus medicinal plant genomics has been a less-focused field of investigation, apart from the sequenced genomes of neem and hemp Owing to the large amounts of specialized metabolites that each of the green plant species produce, they all can be labeled as medicinal plants. For convenience, I have labeled and addressed only those species which are cultivated or exploited for their medicinal properties, either ethnopharmacologically or more recently as a source of new medicine. In this review, I attempt to update both the specialized and non-specialized readers on the present status of medicinal plant genomics and transcriptomics with exhaustive literature search and data mining.
Significant progress to date
The list of sequenced plant genomes include 55-61 dicots, 16 monocots, 18 algae, and one each of pteridophyte, bryophyte, and gymnosperm [CoGePedia: http://genomevolution. org/wiki/index.php/Sequenced_plant_genomes and List of sequenced plant genomes: http://en. wikipedia.org/wiki/List_of_sequenced_plant_ genomes]. Most of these plants were sequenced using Sanger sequencing or hybrid multiplatform approaches, such as 454, SOLiD and Illumina. The most efficient sequencing platforms, such as the Illumina HiSeq 2000, sequence ~100 Gbp/ day, capable of sequencing a 3 Gbp genome at high coverage for >US$10,000 (Schatz et al., 2012) . However, the efforts in sequencing the medicinal plant genomes are very limited. The only medicinal plant genomes sequenced are that of the Neem tree (Azadirachta indica) by GANIT Labs, which reveals a 364 Mbp, with 20,000 genes supported by transcriptomes obtained from shoot, root, leaf, flower, and seeds (Krishnan et al., 2012) , and hemp (Cannabis sativa), that has a 820 Mbp genome and ~30,000 genes (van Bakel et al., 2011) . More recently, the chloroplast genomes of several medicinal plants were reported. These genomes were shown to facilitate population, phylogenetic, and chloroplast-based genetic engineering studies of these medicinal plants, such as that of Salvia miltiorrhiza (Qian et al., 2013) , Mongolia medicine Artemisia frigida (Liu et al., 2013) , and Mahonia bealei (Berberidaceae) (Ma et al., 2013) . All these efforts in genome sequencing could lead to development of stronger comparative genomics resources for furthering the development of medicinal plants.
The launch of Traditional Chinese Medicine (TCM) modernization projects in China and elsewhere in recent years has made remarkable progress of herbal medicine in laboratory development, ingredient profiling, and manufacture production (Zhang et al., 2014) . Expectedly, transcriptomics studies in TCMyielding plants have been the most extensively studied (Hao et al, 2012 (Moerkercke et al., 2013) . Similarly, the transcriptome analysis aided with untargeted metabolic profiling in anti-cancer alkaloid (camptothecin and anthraquinone) producing medicinal plant Ophiorrhiza pumila yielded a wealth of information on this precious genomic resource. Additionally, the transcriptome and metabolome data sets were compared for the alkaloid-producing hairy root with a non-alkaloid producing cell suspension culture (Yamazaki et al., 2013) . Furthermore, Glycyrrhiza plants produce several bioactive phytochemicals. Glycyrrhizin, for example, exhibits pluripotent pharmacological activities. A detailed transcriptome analysis in G. uralensis, provided interesting information on the roles of CYP450s and vacuolar transporters in the biosynthesis of glycyrrhizin (Ramilowski et al., 2013) .
The need for genome-based approaches for the authentication of medicinal plants has been realized (Sucher and Carles, 2008) . This is done by using genome-based features such as traditional PCR-sequencing based methods, molecular marker development, DNA microarray, genotyping, and bar coding. The authors provide a very exhaustive list of 511 medicinal plants and a list of publications on the application of genome-based methods for the authentication of medicinal plants. Hao et al. 2012 , have provided an elaborate account of application of high-throughput sequencing in medicinal plant transcriptome studies, where they have clearly categorized the transcriptomic studies on those used for (i) metabolic pathway studies, and (ii) molecular markers. They also have identified simple sequence repeats (SSRs), single nucleotide polymorphisms (SNPs) and digital gene expression (DGE) as popular ways for molecular marker mining studies. A large-scale and integrative transcriptome sequence and expression profiling study for three species of Asterids that produce medicinally important monoterpenoid indole alkaloids (MIAs) was conducted across a wide range of developmental tissues and in cultured cells and roots, following elicitor treatments in C. roseus. The MIAs are the major source of therapeutics for treatment of cancer (vinblastine, vincristine, and camptothecin), hypertension (reserpine, ajmalicine), malaria (quinine), and analgesics (7-hydroxymitragynine). In this study, exhaustive transcriptomics resources were established in various developmental stages of cells and tissues: in vitro and in vivo, mutant and wild type, and elicitor treated seedlings in C. roseus. This provided a unique and huge resource for the understanding of MIA biosynthesis and a holistic understanding into the metabolism of this important medicinal. The coexpression analysis of MIA biosynthetic pathway genes approach, followed in this comparative study of the three MIA producing species, would enable elucidation of the most chemically prolific, but difficult, species of plants (Góngora-Castillo et al., 2012) .
Furthermore, seven candidate DNA barcodes matK, rbcL, rpoC1, ycf5, ITS2, and ITS) from medicinal plant species were investigated for their PCR amplification efficiency, differential intra-and inter-specific divergences, and the DNA bar-coding gap (Chen et al., 2013) . Results indicated that the second internal transcribed spacer (ITS2) of nuclear ribosomal DNA was rendered most efficient for DNA barcoding applications that was reflected from the ability to successfully discriminate ITS2 in more than 6600 plant samples belonging to 4800 species from 753 diverse genera, a 92.7% success at the species level (Chen et al., 2013 Furthermore, the PhytoMetaSyn (www. phytometacyn.ca) project investigates metabolic pathways of selected important medicinal plants which yield high value metabolites. The final aim is to reconstruct these pathways and model heterologous systems such as the yeast cells to make the commercial scale production of such compounds feasible. Thus, it is an enormous public resource of metabo-genomic information for about 75 plants that are the source of high-value natural products. The annotation results for the transcriptomes of the 20 non-model plant species generated using 454 GS-FLX Titanium and Illumina GA sequencing platforms was provided by a follow-up publication from Xiao et al., 2013 . Although, Xiao et al., 2013 have started to investigate specialized metabolite biosynthesis in non-model plants to be able to establish a data-mining framework applying next-generation sequencing and computational prowess for 75 medicinal plants belonging to 31 plant families, they reported the results obtained from the first twenty species as a proof of concept. These species included Arnica montana, Centella asiatica, Catharanthus roseus, Glaucium flavum, Hypericum perforatum, Lippia dulcis, Papaver bracteatum, Sanguinaria canadensis, Silene vulgaris, Tabernamontana elegans, Valeriana officinalis, and Xanthium strumarium. The transcriptomes were obtained from diverse tissues such as leaf, roots, stem, rhizome, glands, and flowers. These transcriptome projects were centered on six sub-groups (sesquiterpenes, diterpenes, triterpenes, monoterpenoid indole alkaloids, benzylisoquinoline alkaloids, and polyketides) of natural products belonging to three general categories: terpenoids (10 plants), alkaloids (9 plants), and polyketides. The authors clearly maintain that the selection of plant species was based on (a) availability of tissues, (b) commercial weight of key metabolites, (c) extent of understanding biochemical diversity across species and (d) availability of biochemical resources for specialized metabolites (Xiao et al., 2013) . A BLAST portal is publicly available for searching against desirable medicinal plant species for further downstream analyses of gene families and functional genomics studies.
Practical challenges and inherent bottlenecks
Needless to say, there have been transcriptomics investigations that have provided more generalized insights, without actually focusing on the specialized metabolism or carrying out detailed investigations into the biology of medicinal plants. Regardless of the constraints presented towards sequencing of medicinal plants' genomes, such as large and polyploidy genomes, the progress has been inconsistent and a lot remains to be addressed and done. The Table- 1 also reiterates equivocally the mechanistic approaches into transcriptomics investigations for many instances, without any concrete biological insights as well as limited attempts into WGS studies. For example, there are no studies underscoring the effects of domestication on phytomedicinal production by the species of interest, the results of genome duplication events on improvement of metabolically active gene families, reflections in complexity of metabolic networks, the relationship between phenotype to the genotypes, or a correlation of metabolic uniqueness with genomic specialty features of particular medicinal plants. There have been limited attempts in sequencing more and more valuable medicinal plant genomes, owing to reasons that are probably unknown.
The challenges posed by the plant genome sequencing efforts are two-fold. First, the inherent features of plant genomes themselves present big challenges. For example, the genome size, higher levels of ploidy, the complex nature of the genome, higher repetitive features (~80%), transposable elements, heterozygosity, expansive gene families, and huge arrays of noncoding RNAs all add to the complexity of these genomes. Additionally, problems arise using the genome sequencing technologies; things like DNA contamination, sample preparation, sequencing errors, or difficulties in de novo assembly (Carlos et al., 2012) . Apart from these, some challenges associated with medicinal plant genome sequencing are (a) higher contents of secondary metabolites which impede good quality DNA isolations, (b) nonavailability of genomic resources from the taxa under study for annotation and assembly, (c) uniqueness of transcripts that may not have known orthologues in other sequenced and model plant genomes, and (d) unique gene families and uncharacterized genetic elements. Nevertheless, the need for the expansion of sequencing efforts beyond the commercially important crops to include other non-commodity and non-model species has been recently realized (Carlos et al., 2012) . We are still far away from push-button sequencing and assembly of plant genomes into completely finished genomes at lower costs (Schatz et al., 2012) . Approximately two-thirds of the 50,000 different phytomedicinals in use are collected from the wild and 4000-10,000 of them are possibly endangered (Edwards, 2004) . It is important to note that an insignificant number of reports exist on molecular markerbased approaches towards medicinal plant improvement (Canter et al., 2005) . Thus, large-scale bioprospection approaches in phytomedicinal genomics and transcriptomics is still lacking when it comes to exploration of novel plant species.
Concluding remarks and future prospects
The functional genomics approach aided by targeted-metabolite and transcriptome profiling approaches would lead to an efficient way of deciphering novel gene functions involved in specialized metabolic pathways in phytomedicinals. The development of nextgeneration sequencing, coupled with the advancement of computational methods, has allowed researchers to access the transcriptomes of recalcitrant genomes, such as those of medicinal plant species (Góngora-Castillo et al., 2012) . The transcriptomics study concerning medicinal plants has become the most active area in medicinal plant genome research. Hence, the application status of transcriptomics in medicinal plants based on emergence, development, and methodology of transcriptomics have been extensively exploited. The fact that they belong to unique taxonomic families, have limited genomic resources, and are labeled as 'non-model', has hurt the chances of their genomes being sequenced to a greater effect. However, transcriptome sequencing has enjoyed major success. These endeavors in genomics and transcriptomics would enable a robust understanding of metabolic pathways that yield important phytomedicinals and facilitate highly valued metabolic engineering approaches for some rare medicinals.
The optimism is that the '-omics' revolution that is spreading from model species to those with more complex genomes (i.e., 'muddle' species) will influence research and exploitation of medicinal species in a significant manner (Canter et al., 2005 Thus, functional and comparative genomics approaches would enable drug discovery, drug development, and large-scale production of phytomedicinals in the coming future. In combination with widely targeted and untargeted metabolomics, proteomics and transcriptome and genome-based approaches are likely to provide the essential 'healing' touch to the systems biology understanding of phytomedicinal species for researchers in conservation, phytopharmaceuticals, the drug industry, systematic study, and the forensic and herbal industry. 
